Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19
MD Pierre Kory, MD Gianfranco Umberto Meduri, MD Joseph Varon, DO Jose Iglesias, MD Paul E Marik, Jose Iglesias Analysis
Background: After COVID-19 emerged on U.S shores, providers began reviewing the emerging basic science, translational, and clinical data to identify potentially effective treatment options. In addition, a multitude of both novel and repurposed therapeutic agents were used empirically and studied within clinical trials.
Areas of Uncertainty: The majority of trialed agents have failed to provide reproducible, definitive proof of efficacy in reducing the mortality of COVID-19 with the exception of corticosteroids in moderate to severe disease. Recently, evidence has emerged that the oral antiparasitic agent ivermectin exhibits numerous antiviral and anti-inflammatory mechanisms with trial results reporting significant outcome benefits. Given some have not passed peer review, several expert groups including Unitaid/World Health Organization have undertaken a systematic global effort to contact all active trial investigators to rapidly gather the data needed to grade and perform meta-analyses. Data Sources: Data were sourced from published peer-reviewed studies, manuscripts posted to preprint servers, expert meta-analyses, and numerous epidemiological analyses of regions with ivermectin distribution campaigns. Therapeutic Advances: A large majority of randomized and observational controlled trials of ivermectin are reporting repeated, large magnitude improvements in clinical outcomes. Numerous prophylaxis trials demonstrate that regular ivermectin use leads to large reductions in transmission. Multiple, large "natural experiments" occurred in regions that initiated "ivermectin distribution" campaigns followed by tight, reproducible, temporally associated decreases in case counts and case fatality rates compared with nearby regions without such campaigns. Conclusions: Meta-analyses based on 18 randomized controlled treatment trials of ivermectin in COVID-19 have found large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance. Furthermore, results from numerous controlled prophylaxis trials report significantly
References
Agarwal, Mukherjee, Kumar, Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ
Aguirre-Chang, Post-Acute or prolonged COVID-19: treatment with ivermectin for patietns with persistent, or post-acute symptoms ResearchGate
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis
Alam, Pfg, Ivermectin as pre-exposure prophylaxis for COVID 19 among healthcare providers in a selected tertiary hospital in Dhaka an observational study, Eur J Med Health Sci
Anglemyer, Horvath, Bero, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, Cochrane Database Syst Rev
Arevalo, Pagotto, Porfido, Ivermectin reduces coronavirus infection in vivo: a mouse experimental model, bioRxiv,
doi:10.1101/2020.11Atkinson, Audsley, Lieu, Recognition by host nuclear transport proteins drives disorder-to-order transition in Hendra virus V, Sci Rep
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate Covid19 disease: a randomised controlled double blind dose response study in Lagos, medRxiv,
doi:10.1093/qjmed/hcab035Behera, Patro, Singh, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: a matched case-control study
Bernigaud, Guillemot, Ahmed-Belkacem, B en efice de l'ivermectine: de la gale à la COVID-19, un exemple de s erendipit e, Annales de Dermatologie et de V en er eologie
Bray, Rayner, Noël, Ivermectin and COVID-19: a report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses, Antiviral Res
Budhiraja, Soni, Jha, Clinical Profile of First 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: an Indian experience, medRxiv,
doi:10.1101/2020.11.16.20232223Cadegiani, Goren, Wambier, Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients, medRxiv,
doi:10.1101/2020.10.31.20223883Callard, Perego, How and why patients made Long Covid, Soc Sci Med
Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res
Carvallo, Hirsch, Farinella, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19,
doi:10.1101/2020.09.10.20191619v1Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClini-calMedicine
Chachar, Khan, Asif, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci
Chala, Covid-19 in healthcare agents by intensive treatment with ivermectin and iotacarrageenan (Ivercar-Tuc)
Chamie, Real-world evidence: the case of Peru
Chandler, Serious neurological adverse events after ivermectin-do they occur beyond the indication of onchocerciasis?, Am J Trop Med Hyg
Chowdhury, Shahbaz, Karim, A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, Res Square,
doi:10.21203/rs.3.rs-38896/v1Ci, Li, Yu, Avermectin exerts antiinflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol
Consortium, Repurposed antiviral drugs for covid-19-interim WHO solidarity trial results, New Engl J Med
Crump, Omura, Ivermectin,'wonder drug'from Japan: the human use perspective, Proc Jpn Acad Ser B
Dahabreh, Sheldrick, Paulus, Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes, Eur Heart J
Elgazzar, Hany, Youssef, Hafez, Moussa, Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, Res Square,
doi:10.21203/rs.3.rs-100956/v3Espitia-Hernandez, Munguia, Diaz-Chiguer, Effects of Ivermectin-Azithromycin-Cholecalciferol Combined Therapy on COVID-19 Infected Patients: A Proof of Concept Study
Gardon, Gardon-Wendel, Demanga, Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection, Lancet
Gupta, Biswal, Panda, Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin, J Biomol Struct Dyn
Guzzo, Furtek, Porras, Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects, J Clin Pharmacol
Götz, Magar, Dornfeld, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci Rep
H Ector, Roberto, Psaltis, Study of the efficacy and safety of topical ivermectin+ iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Investig
Hashim, Maulood, Rasheed, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq,
doi:10.1101/2020.10.26.20219345Hellwig, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin, Int J Antimicrob Agents
Hermine, Tharaux, Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial, JAMA Intern Med
Horby, Lim, Emberson, Dexamethasone in hospitalized patients with Covid-19-preliminary report, New Engl J Med
Hussien, Abdelaziz, Molecular docking suggests repurposing of brincidofovir as a potential drug targeting SARS-CoV-2 ACE2 receptor and main protease, Netw Model Anal Health Inform Bioinform
Khan, Khan, Debnath, Ivermectin treatment may improve the prognosis of patients with COVID-19, Archivos de Bronconeumología
King, Tessier, Dodge, Inhibition of human adenovirus replication by the importin a/b1 nuclear import inhibitor ivermectin, J Virol
Kircik, Rosso, Layton, Over 25 Years of clinical experience with ivermectin: an overview of safety for an increasing number of indications, J Drugs Dermatol
Kitsios, Dahabreh, Callahan, Can we trust observational studies using propensity scores in the critical care literature? A systematic comparison with randomized clinical trials, Crit Care Med
Kylie, Sivakumaran, Steven, Ivermectin is a specific inhibitor of importin a/b-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, Vivo
Li, Chen, Cao, Extraordinary GU-rich singlestrand RNA identified from SARS coronavirus contributes an excessive immune response, Microbes Infect
Lonjon, Boutron, Trinquart, Comparison of treatment effect estimates from prospective nonrandomized studies with propensity score analysis and randomized controlled trials of surgical procedures, Ann Surg
Lv, Liu, Wang, Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir Res
Mastrangelo, Pezzullo, Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Maurya, A combination of ivermectin and doxycycline possibly blocks the viral entry and modulate the innate immune response in COVID-19 patients, ChemRxiv,
doi:10.26434/chemrxiv.12630539.v1Morgenstern, Redondo, Leon, The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may,
doi:10.1101/2020.10.29.20222505Nallusamy, Mannu, Ravikumar, Shortlisting phytochemicals exhibiting inhibitory activity against major proteins of SARS-CoV-2 through virtual screening, Res Square,
doi:10.21203/rs.3.rs-31834/v1Niaee, Gheibi, Namdar, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, Res Square,
doi:10.21203/rs.3.rs-109670/v1Perera, Tso, Tsang, SARS-CoV-2 virus culture from the upper respiratory tract: correlation with viral load, subgenomic viral RNA and duration of illness, MedRXiv,
doi:10.1101/2020.07.08.20148783Podder, Chowdhury, Sina, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J Med Sci
Polak, Van Gool, Cohen, A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression, Mod Pathol
Portmann-Baracco, Alberti, Accinelli, Antiviral and anti-inflammatory properties of ivermectin and its potential use in covid-19, Arch Bronconeumol
Rajter, Sherman, Fatteh, Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19 (ICON study), Chest
Randomized, Double-Blind Placebo Controlled Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection Clinical-Trials
Ravikirti, Pattadar, Ivermectin as a potential treatment for mild to moderate COVID-19 -a double blind randomized placebo-controlled trial, medRxiv,
doi:10.1101/2021.01.05.21249310Robin, Alam, Saber, A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, J Bangladesh Coll Physicians Surgeons,
doi:10.3329/jbcps.v38i0.47512Rubin, As their numbers grow, COVID-19 "long haulers" stump experts, JAMA
Salvarani, Dolci, Massari, Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial, JAMA Intern Med
Scheim, From cold to killer: how SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, then clot blood cells in pulmonary and systemic microvasculature,
doi:10.2139/ssrn.3706347Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther
Shouman, Hegazy, Nafae, Use of Ivermectin as a Potential Chemoprophylaxis for COV-ID-19 in Egypt: A Randomized Clinical Trial, J Clin Diagn Res
Siegelman, Reflections of a COVID-19 long hauler, JAMA
Soto-Becerra, Culquichicón, Hurtado-Roca, Realworld effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru
Sparsa, Bonnetblanc, Peyrot, Systemic adverse reactions with ivermectin treatment of scabies, Annales de Dermatologie et de Venereologie
Spoorthi, Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV2, Int Arch Integrated Med
Swargiary, Ivermectin as a Promising RNA-dependent RNA Polymerase Inhibitor and a Therapeutic Drug against SARS-CoV2: Evidence from in Silico Studies, Res Square,
doi:10.21203/rs.3.rs-73308/v1Tambo, Khater, Chen, Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty, Infect Dis Poverty
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Res
Varghese, Kaukinen, Gläsker, Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir Res
Veit, Beck, Steuerwald, First case of ivermectin-induced severe hepatitis, Trans R Soc Trop Med Hyg
Yang, Atkinson, Wang, The broad spectrum antiviral ivermectin targets the host nuclear transport importin a/b1 heterodimer, Antivir Res
Young, Ong, Ng, Viral dynamics and immune correlates of COVID-19 disease severity, Clin Infect Dis
Zhang, Song, Ci, Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res
Zhang, Song, Xiong, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol
